Tigecycline (Tygacil)

Medical Letter on Drugs and Therapeutics

Volumn 47, Issue 1217, 2005, Pages 73-74

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

AMYLASE; ANTIBIOTIC AGENT; AZTREONAM; CARBAPENEM DERIVATIVE; CEFOTETAN; CEFOXITIN; CILASTATIN PLUS IMIPENEM; DAPTOMYCIN; ERTAPENEM; GLYCYLCYCLINE DERIVATIVE; LINEZOLID; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TETRACYCLINE; TIGECYCLINE; TIMENTIN; VANCOMYCIN; WARFARIN; DRUG DERIVATIVE; MINOCYCLINE;

ABDOMINAL ABSCESS; ABDOMINAL INFECTION; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ABSCESS; AMYLASE BLOOD LEVEL; ANTIBACTERIAL ACTIVITY; APPENDICITIS; BRAIN PSEUDOTUMOR; BURN INFECTION; CHOLECYSTITIS; CLINICAL STUDY; CLINICAL TRIAL; DIVERTICULITIS; DOSE RESPONSE; DRUG COST; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; HUMAN; HYPERBILIRUBINEMIA; NAUSEA AND VOMITING; PERITONITIS; PHOTOSENSITIVITY; SHORT SURVEY; SKIN INFECTION; UREA NITROGEN BLOOD LEVEL; WOUND INFECTION; ARTICLE; CHEMICALLY INDUCED DISORDER; CONTROLLED CLINICAL TRIAL; INFUSION PUMP; NAUSEA; SKIN DISEASE; VOMITING;

CONTROLLED CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INFUSION PUMPS; MINOCYCLINE; NAUSEA; SKIN DISEASES; VOMITING;

EID: 25144499131     PISSN: 0025732X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (9)

1. JS Solomkin et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 2003; 37:997.
2. E Rubinstein and D Vaughan. Tigecycline: a novel glycylcycline. Drugs 2005; 65:1317.
3. TR Fritsche et al. In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections. Diagn Microbiol Infect Dis 2004; 49:201.
4. C Betriu et al. In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain. Antimicrob Agents Chemother 2002; 46:892.
5. ME Pachon-Ibanez et al. Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem. Antimicrob Agents Chemother 2004; 48:4479.
6. C Betriu et al. Comparative in vitro activities of tigecycline (GAR-936) and other antimicrobial agents against Stenotrophomonas maltophilia. J Antimicrob Chemother 2002; 50:758.
7. DJ Biedenbach et al. In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases. Diagn Microbiol Infect Dis 2001; 40:173.
8. EJ Ellis-Grosse et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005; 41:S341.
9. T Babinchak et al. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005; 41:S354.